StockWatch
·

Asarfi Hospital Ltd Q2 FY27 Results

ASARFIQ2 FY27 Results
Filing
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue53.0411.6%34.2%
Total Income53.7211.7%35.1%
Expenditure45.487.3%37.6%
PBT8.2444.4%16.3%
Net Profit6.0942.8%16.8%
OPM—
NPM11.34%2.47pp2.50pp
EPS3.1042.9%41.5%
View full financials
Q2 FY-2027 RESULTS · ASARFI

Asarfi Hospital Q2 FY27: Consol PAT Up 45% YoY to ₹6.09 Cr, EBITDA Margin Hits 23.4%

PAT +45.16% YoY · revenue +18.15% · margins expanding

13 Nov 2026 · 3 min read
Revenue

₹53.04 Cr

+18.15% YoY

PAT (consolidated)

₹6.09 Cr

+45.16% YoY

Net margin

11.34%

+2.5pp YoY

EPS

₹3.1

Asarfi Hospital's consolidated PAT rose 45.2% YoY to ₹6.09 Cr in Q2 FY27 (quarter ended 30 Sep 2026), outpacing an 18.1% YoY rise in revenue from operations to ₹53.04 Cr, as net margin (PAT/total income) expanded to 11.34% from 9.19% a year ago. QoQ, PAT was up 42.8% and revenue 11.6% versus Q1 FY27 — a hospital operator isn't materially seasonal, so this sequential strength reflects genuine ramp rather than a calendar artifact. Neither the current quarter nor any comparable period carries an exceptional or extraordinary item, so the growth is operational, not one-off driven.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹53.04 Cr+11.6%-34.2%
Expenses₹45.48 Cr+7.3%-37.6%
PAT₹6.09 Cr+42.78%+45.16%
Net margin11.34%+2.5pp+2.5pp
EPS₹3.1+42.9%+41.6%

The margin expansion shows at the operating level too: EBITDA margin (PBT + depreciation + finance cost, over total income) came in at roughly 23.4% this quarter versus ~21.1% a year ago and ~20.8% last quarter — already inside the 22-25% band management guided for FY27 (up from ~20% in FY26) on its May 2026 concall. Against that same call's FY27 revenue target of ₹260 Cr, H1 FY27 consolidated revenue of ₹100.57 Cr is only ~38.7% of the full-year goal, meaning H2 would need to come in near ₹159 Cr — about 58% above H1 — to hit it; that back-loaded requirement makes the revenue-guidance call 'unknown' rather than on-track, resting on the planned ramp of bed capacity (the cancer hospital's expansion from 65 to 150 beds under Vision 2028) actually landing in H2. No consensus estimates for this quarter turned up in a web search — Asarfi carries no active brokerage coverage — so vsStreet is unknown. No standalone management press release accompanied this filing beyond the standard board-outcome letter to BSE, so there is no additional management commentary to reconcile against the print.

₹
149.86175.92201.98228.03254.0918208-1009-0109-2410-1911-1111-13Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹182, down 0.5% over the past month of trading.

₹ Cr
02.735.468.22.07Q2 FY24rev ₹40 Cr2.14Q4 FY24rev ₹44 Cr4.3Q2 FY25rev ₹54 Cr6.27Q4 FY25rev ₹67 Cr7.32Q2 FY26rev ₹81 Cr4.27Q1 FY27rev ₹48 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (4 FY-2026 call)
Asarfi Hospital provided an optimistic outlook, targeting revenue of INR260 crores for FY27, with a mix of organic and inorganic growth, including potential acquisitions. The company aims to significantly scale its bed capacity to over 500 beds by Vision 2028, with aggressive expansion plans for the cancer hospital fro

Standalone and consolidated numbers are nearly identical (standalone PAT ₹6.14 Cr vs consolidated ₹6.09 Cr), confirming the Asarfi Educational Foundation subsidiary's contribution is immaterial to the group result. The quarter's other disclosed events — the FY26 annual report/AGM filing, BSE/NSE migration approval, and cost-auditor appointment — are governance housekeeping rather than operational drivers and don't bear on this print.

  • W1

    H2 FY27 revenue needs to reach ~₹159 Cr (vs ₹100.57 Cr in H1) to hit management's ₹260 Cr FY27 target

  • W2

    Cancer hospital bed expansion from 65 to 150 beds (Vision 2028) — progress check in coming quarters as the key capacity driver

  • W3

    EBITDA margin sustaining the 22-25% band (23.4% this quarter) as new bed capacity comes online, since fresh capacity often dilutes margins initially

Informational and educational content only. Not investment advice.